Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia
Melissa B. Pappalardi(GlaxoSmithKline (United States)), Rab K. Prinjha(GlaxoSmithKline (United States)), Jacques Briand(GlaxoSmithKline (United States)), Dean E. McNulty, David T. Fosbenner(GlaxoSmithKline (United States)), Arthur Groy(GlaxoSmithKline (United States)), Charles F. McHugh(GlaxoSmithKline (United States)), Ashley K. Wiseman(Van Andel Institute), Kristen Wong(GlaxoSmithKline (United States)), Paola Grandi(GlaxoSmithKline (Germany)), Cunyu Zhang(GlaxoSmithKline (United States)), Aidan G. Gilmartin(GlaxoSmithKline (United States)), Sarath Pathuri(The University of Texas MD Anderson Cancer Center), Amy Taylor(GlaxoSmithKline (United States)), Elisabeth A. Minthorn(GlaxoSmithKline (United States)), Anthony J. Jurewicz(GlaxoSmithKline (United States)), Alan P. Graves(GlaxoSmithKline (United States)), Morris Muliaditan(Advanced Pharma), Shawn W. Foley(GlaxoSmithKline (United States)), Susan Merrihew(GlaxoSmithKline (United States)), Thilo Werner(GlaxoSmithKline (Germany)), Nino Campobasso(GlaxoSmithKline (United States)), Mehul Patel(GlaxoSmithKline (United States)), Makda Mebrahtu(GlaxoSmithKline (United States)), H. Christian Eberl(GlaxoSmithKline (Germany)), Mark Cockerill(University of Manchester), Michael Steidel(GlaxoSmithKline (Germany)), Anna Rutkowska(GlaxoSmithKline (Germany)), Alexandra Stowell(University of Manchester), Stuart P. Romeril(GlaxoSmithKline (United States)), Marcus Bantscheff, Thau Ho(GlaxoSmithKline (United States)), Kathryn Keenan(GlaxoSmithKline (United States)), Christian Sherk(GlaxoSmithKline (United States)), Emma Fairweather(University of Manchester), Lourdes Rueda(GlaxoSmithKline (United States)), Charlotte Burt(University of Manchester), Christopher S. Kershaw(University of Manchester), Jessica L. Handler(GlaxoSmithKline (United States)), Kristin Goldberg(University of Manchester), Andrew B. Benowitz(GlaxoSmithKline (United States)), Wendy A. Kellner(GlaxoSmithKline (United States)), Mei Li(Soochow University), Roger J. Butlin(University of Manchester), Ali Raoof(University of Manchester), P Chapman(University of Manchester), Helai P. Mohammad(GlaxoSmithKline (United States)), Jon‐Paul Jaworski(GlaxoSmithKline (United States)), Xing Zhang(Emory University), J.R. Horton(The University of Texas MD Anderson Cancer Center)
Cited by 279
Related Papers
City of Quartz: Excavating the Future in Los Angeles.
|Contemporary Sociology A Journal of Reviews|1991|2k
Quantitative mass spectrometry in proteomics: a critical review
|Analytical and Bioanalytical Chemistry|2007|1.7k
Selenomethionyl proteins produced for analysis by multiwavelength anomalous diffraction (MAD): a vehicle for direct determination of three‐dimensional structure.
|The EMBO Journal|1990|1k
GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained <i>In Vivo</i> Pathway Inhibition
|Clinical Cancer Research|2011|600
Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology
|Molecular Psychiatry|2013|440